(ALNY) Alnylam Pharmaceuticals, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALNY) Alnylam Pharmaceuticals, Inc. Complete Analysis Pack
Dive Deeper Into the Growth Paths Behind the Analysis
This Alnylam Pharmaceuticals, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification to support strategy, investing, or planning. This page displays a real preview of the analysis so you can review style and substance before buying; purchase the full version to receive the complete, ready-to-use report.
Market Penetration
ONPATTRO in hereditary transthyretin-mediated amyloidosis polyneuropathy
ONPATTRO is one of Alnylam’s 3 approved therapies and is already sold in hereditary transthyretin-mediated amyloidosis polyneuropathy, so the Ansoff play is market penetration, not new-market entry. The goal is to win more of the diagnosed adult base in existing markets through specialist adoption, earlier diagnosis, and better persistence in the labeled population.
That matters because hATTR amyloidosis is rare, with estimated global prevalence around 50,000 people, so growth depends on finding and keeping treated patients, not broadening the disease label. In practice, stronger neurology and cardiology referral pathways can lift starts and refills even without new geography.
GIVLAARI in adult acute hepatic porphyria
GIVLAARI is already in Alnylam Pharmaceuticals, Inc. commercial portfolio, so growth in adult acute hepatic porphyria depends on deeper use in the current labeled segment. In ENVISION, it cut annualized porphyria attacks by 74% versus placebo, supporting uptake among treated adults who still have attacks or hemin use.
With AHP remaining ultra-rare, the key lever is finding more eligible adults and converting diagnosed patients to therapy.
OXLUMO in primary hyperoxaluria type 1
OXLUMO, Alnylam Pharmaceuticals, Inc.'s RNAi drug for primary hyperoxaluria type 1 (PH1), already sits in the rare renal franchise, so market penetration means taking more share from the current PH1 pool, not finding a new disease. PH1 is ultra-rare and often diagnosed late, which limits starts. Growth comes from faster testing, more referral to specialist centers, and better treatment persistence.
Rare-disease specialty-center focus
Alnylam Pharmaceuticals, Inc. grows in rare disease by winning specialist centers, where hATTR, AHP, and PH1 treatment decisions are made and undiagnosed patients are found. That matters because hATTR affects about 50,000 people worldwide, while PH1 and AHP are ultra-rare, so penetration depends on expert prescribers, referral pathways, and diagnosis rates. In FY2025, this focus supports repeat use in a very small but high-value base.
- Target specialist prescribers first
- Find undiagnosed patients fast
- Best fit: hATTR, AHP, PH1
Sanofi Genzyme commercialization support
Sanofi Genzyme gives Alnylam Pharmaceuticals, Inc. a commercial bridge in existing markets, widening access for approved RNAi medicines and helping convert launch activity into higher uptake. The alliance is part of a broader RNAi development and commercialization tie-up, so market penetration depends less on new geographies and more on deeper reach in the same patient pools.
- Broader field force and payer reach
- Higher access in current markets
- Faster uptake for approved products
For market penetration, the main win is execution: more patients reached, fewer access frictions, and better pull-through for current brands. In practice, this matters most where treatment adoption is still early and each incremental prescription lifts share without needing a new product launch.
Alnylam’s Growth Hinges on Deeper Rare-Disease Penetration
Market penetration for Alnylam Pharmaceuticals, Inc. means pushing ONPATTRO, GIVLAARI, and OXLUMO deeper into already approved rare-disease pools, not opening new markets. The main levers are faster diagnosis, more specialist referrals, and better persistence in hATTR, AHP, and PH1.
With hATTR affecting about 50,000 people worldwide and AHP and PH1 remaining ultra-rare, growth comes from converting more diagnosed adults in FY2025.
| Brand | Use | Penetration lever |
|---|---|---|
| ONPATTRO | hATTR | Earlier diagnosis |
| GIVLAARI | AHP | More eligible starts |
| OXLUMO | PH1 | Specialist referrals |
What is included in the product
Detailed Word Document
Provides a clear Ansoff Matrix overview of Alnylam Pharmaceuticals, Inc.’s growth strategy across existing and new products and markets
Editable Excel File
Provides a clear Alnylam Pharmaceuticals Ansoff Matrix for quick growth strategy alignment across pipeline, markets, and expansion options.
Reference Sources
Cites primary, regulatory, and industry sources to validate Alnylam growth paths and speed due diligence for Ansoff Matrix decisions.
Market Development
Givosiran in adolescent acute hepatic porphyria
Givosiran’s move into adolescent acute hepatic porphyria (AHP) is market development: the drug stays the same, but Alnylam Pharmaceuticals, Inc. expands to a younger patient base. AHP is ultra-rare, with an estimated prevalence of about 1 in 20,000 people in Europe, so even small age-segment gains can matter. This adds pediatric demand to Alnylam Pharmaceuticals, Inc.’s hepatic franchise and widens the addressable market.
Patisiran in transthyretin amyloidosis with cardiomyopathy
Patisiran’s move into transthyretin amyloidosis with cardiomyopathy is classic market development: same RNAi asset, new disease setting. Alnylam’s APOLLO-B data showed patients with ATTR-CM had better functional and quality-of-life outcomes over 12 months, supporting a broader cardiac label path. That expands Onpattro from neurology into cardiology and opens a larger, high-value rare-disease market.
OXLUMO expansion beyond PH1
Alnylam Pharmaceuticals, Inc. is pushing OXLUMO beyond its PH1 base into advanced PH1 and recurrent kidney stones, widening the renal addressable market. PH1 is ultra-rare, affecting about 1 in 58,000 live births, while recurrent kidney stones hit roughly 1 in 10 adults, so the move targets a much larger patient pool. This is market development: the same drug, but more eligible patients beyond the original PH1 label.
Partner-led ex-U.S. reach
Alnylam Pharmaceuticals, Inc. uses partner-led ex-U.S. reach to sell the same RNAi drugs in more countries, so this is market development, not product change. Sanofi Genzyme has helped extend commercialization for medicines like Onpattro and Amvuttra beyond Alnylam's core base. In 2025, this model mattered because it let Alnylam broaden access without rebuilding every local sales force.
- Same medicines, wider geography
- Partners lower launch cost
- Faster entry into new markets
Broader rare-disease patient identification
Alnylam Pharmaceuticals, Inc. can grow through market development by finding more diagnosed patients for its 4 approved medicines in new regions and care settings. Its rare-disease franchise is built for underdiagnosed groups, so better screening in cardiology, neurology, and nephrology can add patients without changing the product.
- 4 approved medicines support expansion
- New diagnoses drive growth, not reformulation
- Referral paths widen in specialty care
Alnylam’s 2025 Growth: Same Drugs, Bigger Markets
Alnylam Pharmaceuticals, Inc. uses market development by pushing the same RNAi drugs into new patients, diseases, and geographies. In 2025, its 4 approved medicines expanded through younger AHP patients, ATTR-CM, broader PH1 use, and partner-led ex-U.S. sales.
This matters because rare-disease diagnosis is the bottleneck, not the molecule; better screening in cardiology, neurology, and nephrology can lift demand without new product builds.
| Move | Market | Why it fits |
|---|---|---|
| Givosiran | Adolescent AHP | Same drug, younger patients |
| Patisiran | ATTR-CM | Same asset, new setting |
| OXLUMO | Advanced PH1, recurrent stones | Same drug, wider pool |
Get Your Copy
Alnylam Pharmaceuticals, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable Ansoff Matrix for Alnylam Pharmaceuticals, Inc.
Product Development
Vutrisiran for ATTR amyloidosis
Vutrisiran is Alnylam Pharmaceuticals, Inc.’s RNAi therapy for ATTR amyloidosis, with AMVUTTRA sales reaching $0.5 billion in 2024, up 77% year over year. That makes it a clear product development move: a new product built for Alnylam Pharmaceuticals, Inc.’s existing amyloidosis base, aimed at deepening share in a market where ATTR-CM affects about 300,000 people worldwide. The 2024 HELIOS-B data also supported broader use in ATTR cardiomyopathy.
Fitusiran for hemophilia and bleeding disorders
Fitusiran is Alnylam Pharmaceuticals, Inc.'s RNAi therapy for hemophilia A and B and other bleeding disorders, aimed at a large, established hematology market. In 2025, its ATLAS studies showed annualized bleeding rates below 1 in many patients, with dosing as infrequent as once every 2 months. That would expand Alnylam beyond approved rare-disease products into a broader treatment category.
Inclisiran for hypercholesterolemia
Inclisiran is a product development move: it brings a new RNAi therapy into the huge, mature hypercholesterolemia market, where about 86 million U.S. adults have total cholesterol of 200 mg/dL or higher. Leqvio’s twice-yearly dosing helps it stand out in a crowded statin and PCSK9 space. Because the market already exists and the product is new, this fits Ansoff product development.
Cemdisiran for complement-mediated disorders
Cemdisiran is Alnylam Pharmaceuticals, Inc.’s siRNA program for complement-mediated disorders, so it is a product development play inside an established immune and rare-disease market. Alnylam’s 2024 revenue was about $1.3 billion, and this kind of launch helps expand its RNAi base beyond current franchises. A one-line read: it adds a new therapy class to a known clinical area.
- New product, same disease space
- Targets complement-driven pathology
- Extends RNAi into adjacent markets
Zilebesiran for hypertension
Zilebesiran is a product-development move for Alnylam Pharmaceuticals, Inc. because it targets hypertension, a huge existing market with about 1.3 billion adults worldwide affected. In clinical testing, a single 300 mg dose cut systolic blood pressure by up to 20.3 mmHg at 3 months in early studies, showing a clear shot at a crowded treatment class. If approved, it would compete inside an already served market, not create a new one.
- Huge current market: 1.3 billion adults
- New therapy for an existing disease
- Single-dose RNAi profile may aid adherence
- Direct fit for product-development strategy
Alnylam Expands RNAi Pipeline Across Big Existing Markets
Alnylam Pharmaceuticals, Inc.’s product development is clear: it is pushing new RNAi drugs into existing disease markets. In 2025, fitusiran cut annualized bleeding rates below 1 in many patients, and HELIOS-B kept vutrisiran in the ATTR field. Zilebesiran and cemdisiran do the same in hypertension and complement disease.
| Program | 2025 fit |
|---|---|
| Fitusiran | Hemophilia |
| Vutrisiran | ATTR |
| Zilebesiran | Hypertension |
Diversification
ALN-HBV02 for chronic hepatitis B virus infection
ALN-HBV02 targets chronic hepatitis B virus infection, a market with about 254 million people living with HBV worldwide and roughly 1.1 million deaths each year. For Alnylam Pharmaceuticals, Inc., that moves the company into a new infectious-disease field with a new product candidate. It is a clear diversification step beyond its approved rare-disease base.
ALN-HSD for non-alcoholic steatohepatitis
ALN-HSD targets non-alcoholic steatohepatitis, a new product in a new metabolic liver-disease market, so it fits Alnylam Pharmaceuticals, Inc. diversification. NASH affects about 25% of adults worldwide, and the field has moved fast since the first MASH drug approval in 2024, but it is still an early, high-need space. This expands Alnylam Pharmaceuticals, Inc. beyond rare disease into a much larger commercial market.
ALN-AAT02 for AAT deficiency-associated liver disease
ALN-AAT02 targets AAT deficiency-associated liver disease, opening a new market outside Alnylam Pharmaceuticals, Inc.’s approved RNAi portfolio. That makes it a clear diversification move in the Ansoff Matrix, because it extends the Company Name into a new disease segment rather than just widening current use. It also deepens Alnylam Pharmaceuticals, Inc.’s liver-disease focus.
Regeneron collaboration for ocular RNAi targets
Alnylam Pharmaceuticals, Inc. and Regeneron’s ocular RNAi work is diversification: it moves Alnylam into a new therapy area with a new product set, beyond its 4 approved medicines. The deal adds eye-disease reach to its RNAi platform and broadens the pipeline beyond current indications.
That matters because ocular targets can open a large adjacent market without building a totally new modality from scratch.
- New therapeutic area: ophthalmology
- New product set: ocular RNAi targets
- Extends beyond 4 approved medicines
Regeneron collaboration for CNS RNAi targets
Alnylam Pharmaceuticals, Inc.'s Regeneron collaboration on CNS RNAi targets is a clear diversification move because it pushes both the product set and the addressable market beyond its core commercial base. Central nervous system RNAi could open drug opportunities in disorders where delivery has been a major barrier, expanding Alnylam's reach into a new therapeutic arena.
- CNS targets = new market
- Outside core commercial base
- Product scope also expands
- Higher long-run option value
Alnylam Expands Beyond Rare Disease Into Big New Markets
Alnylam Pharmaceuticals, Inc. is using diversification to move beyond rare disease and into larger new markets. ALN-HBV02, ALN-HSD, and ALN-AAT02 expand the Company Name into hepatitis B, metabolic liver disease, and AAT deficiency, while the Regeneron eye and CNS RNAi deals add new therapeutic areas.
| Target | Market cue |
|---|---|
| HBV | 254M cases |
| NASH/MASH | 25% of adults |
| Core base | 4 approved medicines |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.